ROBERT A. KREISBERG, M.D.
This content is PDF only. Please click on the PDF icon to access.
Two new second-generation sulfonylurea agents, glipizide (Glucatrol; Roerig, New York, New York) and glyburide (Diabeta; Hoechst-Roussel, Somerville, New Jersey; Micronase; Upjohn Company, Kalamazoo, Michigan) have been approved by the Food and Drug Administration for the treatment of patients with type II or non-insulin-dependent diabetes mellitus. What should be our position on their use for type II diabetes in newly diagnosed patients who are eligible for this type of agent, and in established patients whose diabetes is not well controlled with first-generation sulfonylureas?
The second-generation sulfonylureas differ from the first generation in structure and potency (1). The aliphatic side-chains of tolbutamide
KREISBERG RA. The Second-Generation Sulfonylureas: Change or Progress?. Ann Intern Med. ;102:125–126. doi: 10.7326/0003-4819-102-1-125
Download citation file:
Published: Ann Intern Med. 1985;102(1):125-126.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use